Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068195 | 1.00 | ADORA2B (0.64) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL13464478 | 0.81 | ADORA2B (0.73) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL8005373 | 0.81 | ADORA1 (0.76) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL4990200 | 0.80 | ADORA1 (0.62) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL7431499 | 0.79 | ADORA1 (0.70) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL7439146 | 0.79 | ADORA1 (0.70) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL4982699 | 0.79 | ADORA1 (0.66) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL14343537 | 0.79 | ADORA1 (0.74) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL3696129 | 0.78 | ADORA1 (0.66) | ADORA2BADORA1ADORA2AADORA3MEN1 | |
| SCHEMBL4986845 | 0.78 | ADORA1 (0.69) | ADORA2BADORA1ADORA2AADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616817-A2 | METHODS OF USE AND KIT FOR MEASUREMENT OF LIPOPOLYSACCHARIDE WITH A TIME RESOLVED FLUORESCENCE BASED ASSAY | Endacea, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130183696-A1 | METHODS OF USE AND KIT FOR MEASUREMENT OF LIPOPOLYSACCHARIDE WITH A TIME RESOLVED FLUORESCENCE BASED ASSAY | WILSON CONSTANCE NEELY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037361-A2 | METHODS OF USE AND KIT FOR MEASUREMENT OF LIPOPOLYSACCHARIDE WITH A TIME RESOLVED FLUORESCENCE BASED ASSAY | ENDACEA, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-0794963-B1 | XANTHINE DERIVATIVES COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | US HEALTH (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030114375-A1 | Method for treating cystic fibrosis | THE GOVERNMENT OF THE USA, DEPT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH | 2003-06-19 | — | — | US | disclosed |
| US-6083954-A | ADMINISTERING PURINE DERIVATIVE | US HEALTH (US) | 2000-07-04 | — | — | US | disclosed |
| US-5877179-A | CYSTIC FIBROSIS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0794963-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016084-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114375-A1 | Method for treating cystic fibrosis | CFTR, ADORA1, ADORA3 | ADORA2B 27/4885ADORA1 2/4885ADORA2A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.